Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa

PLoS Neglected Tropical Diseases

Volumn 10, Issue 7, 2016, Pages

  Meiring, Susan ^a   Fortuin de Smidt, Melony ^a,b   Kularatne, Ranmini ^b,c   Dawood, Halima ^d   Govender, Nelesh P ^a,b,e  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CREATININE; HEMOGLOBIN; POTASSIUM; POTASSIUM CHLORIDE; AMPHOTERICIN B; AMPHOTERICIN B, DEOXYCHOLATE DRUG COMBINATION; ANTIFUNGAL AGENT; DEOXYCHOLIC ACID; DRUG COMBINATION;

ANEMIA; ARTICLE; CROSS-SECTIONAL STUDY; CRYPTOCOCCAL MENINGITIS; FATALITY; FEMALE; GLASGOW COMA SCALE; HOSPITAL MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDRATION; HYPOKALEMIA; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OBSERVATIONAL STUDY; PHYSICIAN ATTITUDE; PREVALENCE; PROSPECTIVE STUDY; COMPLICATION; DRUG COMBINATION; HIV INFECTIONS; HOSPITALIZATION; MENINGITIS, CRYPTOCOCCAL; RETROSPECTIVE STUDY; SOUTH AFRICA;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; PREVALENCE; RETROSPECTIVE STUDIES; SOUTH AFRICA;

EID: 84980329052     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004865     Document Type: Article

References (29)

1. Park BJ, Shetty S, Ahlquist A, Greenbaum A, Miller JL, Motsi A, et al. Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa. Int JSTD AIDS. 2011;22(4):199–203.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM, Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30. doi: 10.1097/QAD.0b013e328322ffac19182676
3. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46(11):1694–701. doi: 10.1086/58766718433339
4. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: Implications for improving outcomes. Clin Infect Dis. 2014;58(5):736–45. doi: 10.1093/cid/cit79424319084
5. Loyse A, Dromer F, Day J, Lortholary O, Harrison TS, Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother. 2013;68(11):2435–44. doi: 10.1093/jac/dkt22123788479
6. Govender NP, Roy M, Mendes JF, Zulu TG, Chiller TM, Karstaedt AS, Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa. HIV Med. 2015;16(8):468–76. doi: 10.1111/hiv.1224525689352
7. HIV Clinicians Society of South AfricaGovender NP, Meintjes G, Bicanic T, Dawood H, Harrison T, et al. Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 updateSAJHIVMed. 2014;14(2):76–86.
8. McCarthy KM, Meintjes G, Arthington-Skaggs B, Bicanic T, Cotton M, Chiller T, et al. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. SAJHIVMed. 2007;Spring edition:25–35.
9. Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368(14):1291–302. doi: 10.1056/NEJMoa111040423550668
10. Govender NP, Meintjes G, Banoo S, Access to flucytosine for HIV-infected patients with cryptococcal meningitis—an urgent need.SAMJ. 2014;104(9):594–5. 26307779
11. GERMS-SA Annual Report 2008 [Internet]. 2009. Available from: http://nicd.ac.za/?page=germs-sa&id=97.
12. GERMS-SA Annual Report 2010 [Internet]. 2011. Available from: http://nicd.ac.za/?page=germs-sa&id=97.
13. Malahyde Information Systems. SA Electronic Package Inserts: Fungizone Intravenous. 2005.
14. Gallis HA, Drew RH, Pickard WW, Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12(2):308–29. 2184499
15. Ochieng PO, McLigeyo SO, Amayo EO, Kayima JK, Omonge EO, Nephrotoxicity of amphotericin B in the treatment of cryptococcal meningitis in acquired immunodeficiency syndrome patients. East AfrMed J. 2009;86(9):435–41.
16. Bicanic T, Bottomley C, Loyse A, Brouwer AE, Muzoora C, Taseera K, et al. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrob Agents Chemother. 2015;59(12):7224–31. doi: 10.1128/AAC.01698-1526349818
17. Thakur CP, Kumar A, Mitra DK, Roy A, Sinha AK, Ranjan A, . Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride. AmJTropMed Hyg. 2010;83(5):1040–3.
18. Echevarria J, Seas C, Cruz M, Chavez E, Campos M, Cieza J, et al. Oral rehydration solution to prevent nephrotoxicity of amphotericin B. AmJTropMed Hyg. 2006;75(6):1108–12.
19. Bahr NC, Rolfes MA, Musubire A, Nabeta H, Williams DA, Rhein J, et al. Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings. Open Forum Infect Dis. 2014;1(2):ofu070. doi: 10.1093/ofid/ofu07025734140
20. World Health OrganisationRapid Advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva, Switzerland: World Health Organisation, 2011.
21. Meiring ST, Quan VC, Cohen C, Dawood H, Karstaedt AS, McCarthy KM, et al. A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005–2007. AIDS. 2012;26(18):2307–14. doi: 10.1097/QAD.0b013e328357056722739390
22. Division of AIDS, Regulatory Support Centre. Division of AIDS Table for Grading the Severty of Adult and Pediatric Adverse Events. Version 1.0 December 2004; Clarification August 20092014.
23. Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis. 2013;13(7):629–37. doi: 10.1016/S1473-3099(13)70078-123735626
24. Lewis RE, Viale P, Update on Amphotericin B Pharmacology and Dosing for Common Systemic Mycoses. Curr Fung Infect Reports. 2012;6(4):349–57.
25. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008;47(1):123–30. doi: 10.1086/58879218505387
26. Kerkhoff AD, Lawn SD, Schutz C, Burton R, Boulle A, Cobelens FJ, et al. Anemia, Blood Transfusion Requirements and Mortality Risk in Human Immunodeficiency Virus-Infected Adults Requiring Acute Medical Admission to Hospital in South Africa. Open Forum Infect Dis. 2015;2(4):ofv173. doi: 10.1093/ofid/ofv17326730391
27. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997;11(12):1463–71. 9342068
28. Loo AS, Muhsin SA, Walsh TJ, Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf. 2013;12(6):881–95. doi: 10.1517/14740338.2013.82716823931455
29. Rolfes MA, Hullsiek KH, Rhein J, Nabeta HW, Taseera K, Schutz C, et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis. 2014;59(11):1607–14. doi: 10.1093/cid/ciu59625057102